Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Taltz alone.

Weight loss from Eli Lilly’s Zepbound drug can reportedly be reversed if users stop treatment, according to a new study. In a study published in the journal JAMA, patients on the drug who struggled with non-diabetic obesity were reported to have 14 per ...

Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others? The question was explored in a new study published this month in The New England Journal of Medicine. Researchers compared the ...

The first pills are expected to hit the market next month and attract people who don’t want to give themselves shots.

Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed Wegovy for weight loss in a clinical trial sponsored by Eli Lilly.

Millions of Americans are using GLP-1s. But so far, there has been comparatively less research on what happens when users stop taking the drugs.

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found.

Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his studies and won a national competition called FameLab in 2020.